drugset / Trial / NCT07169162

ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder

NCT07169162

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, flexible dose-titration, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of ADZENYS XR-ODT compared to placebo in children with ADHD.

Timeline

Start
2019-05
Primary completion
2025-09-05
Completion
2025-09-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphetamine Unknown 3.1 mg Oral
Subject Amphetamine Unknown 6.3 mg Oral
Subject Amphetamine Unknown 9.4 mg Oral
Subject Amphetamine Unknown 12.5 mg Oral
Subject Amphetamine Unknown 15.7 mg Oral
Subject Amphetamine Unknown 18.8 mg Oral